Market Indices
Sector Heatmap
KYMR — Kymera Therapeutics, Inc. Common Stock
NasdaqKymera Therapeutics, Inc. Common Stock
- O
- 108.38
- H
- 109.92
- L
- 103.33
- V
- 729.51K
KYMR — Latest News & Headlines
15 StoriesA 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. - stocktitan.net
A 30,000-share sale is planned by Kymera Therapeutics (KYMR) officer and director Nello Mainolfi. stocktitan.net
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells 30,000 Shares of Company Stock MarketBeat
Trading Systems Reacting to (KYMR) Volatility - Stock Traders Daily
Trading Systems Reacting to (KYMR) Volatility Stock Traders Daily
KYMR Maintained by Citigroup -- Price Target Raised to $150 - GuruFocus
KYMR Maintained by Citigroup -- Price Target Raised to $150 GuruFocus
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock - Investing.com
Kymera Therapeutics CEO Nello Mainolfi sells $3.4 million in stock Investing.com
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 Moomoo
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. - stocktitan.net
After exercising options at $2.08 a share, Kymera Therapeutics (KYMR) CEO sells 30,000 shares. stocktitan.net
FIG Stock Hits Record Low After RBC Capital Questions Monetization Of AI Features — But Retail Is Bullish - Stocktwits
FIG Stock Hits Record Low After RBC Capital Questions Monetization Of AI Features — But Retail Is Bullish Stocktwits
B.Riley keeps Buy rating for Kymera Therapeutics stock - AD HOC NEWS
B.Riley keeps Buy rating for Kymera Therapeutics stock AD HOC NEWS
Piper Sandler reiterates Kymera Therapeutics stock rating at $140 - Investing.com
Piper Sandler reiterates Kymera Therapeutics stock rating at $140 Investing.com
Goldman Sachs resumes Kymera Therapeutics stock coverage - Investing.com
Goldman Sachs resumes Kymera Therapeutics stock coverage Investing.com
Kymera Therapeutics stock reports 465.2 percent revenue growth - AD HOC NEWS
Kymera Therapeutics stock reports 465.2 percent revenue growth AD HOC NEWS
B.Riley reiterates Kymera Therapeutics stock rating on new trial data - Investing.com Nigeria
B.Riley reiterates Kymera Therapeutics stock rating on new trial data Investing.com Nigeria
Citi raises Kymera Therapeutics stock price target on drug potential By Investing.com - Investing.com South Africa
Citi raises Kymera Therapeutics stock price target on drug potential By Investing.com Investing.com South Africa
Kymera Therapeutics Slides After Red‑Hot Drug Optimism - TipRanks
Kymera Therapeutics Slides After Red‑Hot Drug Optimism TipRanks